Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
| Title: | Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC |
|---|---|
| Authors: | Uehara, Y., Takeyasu, Y., Yoshida, T., Tateishi, A., Torasawa, M., Hosomi, Y., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., Ohe, Y. |
| Source: | In ESMO Real World Data and Digital Oncology September 2024 5 |
| Database: | ScienceDirect |
| ISSN: | 29498201 |
|---|---|
| DOI: | 10.1016/j.esmorw.2024.100058 |
| Published in: | ESMO Real World Data and Digital Oncology |
| Language: | English |